ArticleJournal of surgical oncology2026
Higher Composite Social Determinants of Health Scores Are Associated With Worse Survival in Patients With Small Bowel Neuroendocrine Tumors.
Article in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Survival Impact of Textbook Oncological Outcomes and SDHs for Patients with Operable Esophageal Cancer.Cancers · 2026Article
- Higher Composite Social Determinants of Health Scores Are Associated With Worse Survival in Patients With Small Bowel Neuroendocrine Tumors.Journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPatients with early-stage well-differentiated small bowel neuroendocrine tumors (sbNETs) experience favorable prognosis with timely diagnosis and treatment. However, the impact of social determinants of health (SDH) and care at Minority-Serving Hospitals (MSHs) on outcomes remains understudied. This study evaluates the combined influence of SDH and hospital type on long-term survival in sbNETs.
methodsThe 2010-2020 National Cancer Database was queried for adults with G1/G2 sbNETs, Stage I/II disease, who underwent surgical resection. Patients with G3 NETs, Stage III/IV disease, neuroendocrine carcinoma, duodenal primary tumors, or incomplete follow-up were excluded. A composite SDH score was developed using four sociogeographic factors: (1) low income, (2) low education, (3) rurality, (4) travel distance > 250 miles. Patients were categorized as SDH+ (score 0-1) or SDH- burden (score 2-4). Hospitals in the top decile for Black and Hispanic representation were classified as MSHs. Kaplan-Meier and Cox regression analyses were performed.
resultsAmong 2688 patients (median age 64; 48% female), 57% were SDH-. Five-, 10-, and 15-year survival rates were 79%, 62%, and 49%, respectively. At MSHs, 5-year survival was 82% for SDH+ versus 63% for SDH-. At non-MSHs, survival was 82% for SDH+ versus 77% for SDH-. Median survival for SDH- patients was 11 years at MSHs versus 12 at non-MSHs. In regression analysis, SDH- status was linked to worse survival (HR 1.24, p < 0.001); treatment at non-MSHs predicted better survival (HR 0.41, p < 0.001). Black patients had higher mortality risk (HR 1.20, p = 0.002); no difference was observed for Hispanic patients.
conclusionHigher SDH burden and treatment at MSHs were associated with decreased survival in early-stage sbNETs. Implementing a composite SDH score in clinical practice may provide a practical tool for risk stratification and guide equity-focused interventions for patients with sbNETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.